The ranking in this dataset is led by an academic research foundation with 13 of the 90 records in scope, with the field concentrated further among a small group of universities and biotech entities. The top five assignees together hold 60.0% of all records, and the top ten hold 94.4%, so a small number of institutions effectively define the prior art in this space. Most of the leading names are academic research foundations rather than large pharmaceutical companies, which matters for licensing strategy since these institutions typically license out rather than practice the technology themselves.

No, not on current evidence. Annual filings peaked at 15 records in 2020 and then declined, falling from 9 in 2021 to 2 in 2024, a 78% drop over that span. The 2025 and 2026 counts should not be read as continued decline, since publication typically lags filing by about 18 months and those years are still filling in — but the multi-year trend through 2024 is a real contraction, not a data artifact.

US8586707B2 covers a photochemically-based [3+2] cycloaddition method for preparing stapled peptides, including helical variants with increased helicity, thermal stability and cell permeability. It is assigned to The Research Foundation of State University of New York and sits within the same cluster as the field’s most-cited records, including WO2010033617A2 and US20100093086A1 on stapled peptide synthesis more broadly. Anyone developing a new stapling method should review this claim set closely, particularly if the approach uses photochemical or cycloaddition-based ring closure rather than a distinct chemistry.